Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer

被引:47
作者
Hsu, Charles C. [1 ,6 ]
Wolfgang, Christopher L. [2 ,5 ]
Laheru, Daniel A. [3 ,5 ]
Pawlik, Timothy M. [2 ,5 ]
Swartz, Michael J. [1 ]
Winter, Jordan M. [2 ]
Robinson, Raymond [1 ]
Edil, Barish H. [2 ,5 ]
Narang, Amol K. [1 ]
Choti, Michael A. [2 ]
Hruban, Ralph H. [4 ,5 ]
Cameron, John L. [2 ,5 ]
Schulick, Richard D. [2 ,5 ]
Herman, Joseph M. [1 ,5 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD 21231 USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
[5] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA
[6] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
关键词
Early mortality; Risk score; Resectable; Pancreatic adenocarcinoma; GEMCITABINE-BASED CHEMORADIATION; PREOPERATIVE CHEMORADIATION; ADJUVANT CHEMORADIATION; DUCTAL ADENOCARCINOMA; CURATIVE RESECTION; SURVIVAL; PANCREATICODUODENECTOMY; CHEMOTHERAPY; RADIATION; CHEMORADIOTHERAPY;
D O I
10.1007/s11605-011-1811-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Identifying pancreatic cancer patients at high risk of early mortality following pancreaticoduodenectomy (PD) is important for treatment decisions in a multidisciplinary setting. This study examines the preoperative predictors of early mortality following PD and combines these variables into an early mortality risk score (EMRS). Medical records of patients who underwent PD for pancreatic adenocarcinoma at the Johns Hopkins Hospital between 30 August 1993 and 28 February 2005 were reviewed. Cox proportional hazards analysis was performed to identify predictors of early mortality, defined as death at 9 and 12 months. EMRS was constructed from univariate associated risk factors (age > 75 years, tumor size a parts per thousand yen3cm, poor differentiation, co-morbid diseases) with each factor assigned 1 point (range of 0-4). EMRS was evaluated as an independent predictor of death at 9 and 12 months. On univariate analysis, risk factors for death at 9 months included age a parts per thousand yen75 years (RR, 1.6; p = .009), comorbid disease (RR, 1.5; p = 0.020), tumor a parts per thousand yen3 cm (RR, 1.4; P = 0.050), and poor differentiation (RR, 2.1; P < 0.001). EMRS was associated with early mortality among those who did (p = 0.038) and did not receive adjuvant treatment (p < 0.001). A modified EMRS without tumor differentiation was also associated with early mortality (p < 0.001). Results persisted when reanalyzed using death at 12 months. EMRS may identify patients at risk of early mortality following PD who may be candidates for alternatively sequenced treatment protocols. Prospective validation of this EMRS is needed.
引用
收藏
页码:753 / 761
页数:9
相关论文
共 33 条
[1]   Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: Feasibility, efficacy, and survival [J].
Allendorf, John D. ;
Lauerman, Margaret ;
Bill, Aliye ;
DiGiorgi, Mary ;
Goetz, Nicole ;
Vakiani, Efsevia ;
Remotti, Helen ;
Schrope, Beth ;
Sherman, William ;
Hall, Michael ;
Fine, Robert L. ;
Chabot, John A. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (01) :91-100
[2]  
[Anonymous], INT J RAD ONCOL BIOS
[3]  
[Anonymous], NCCN PRACT GUID ONC
[4]   Resectable Pancreatic Cancer: Who Really Benefits From Resection? [J].
Barugola, Giuliano ;
Partelli, Stefano ;
Marcucci, Stefano ;
Sartori, Nora ;
Capelli, Paola ;
Bassi, Claudio ;
Pederzoli, Paolo ;
Falconi, Massimo .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (12) :3316-3322
[5]   Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration [J].
Tara M. Breslin ;
Kenneth R. Hess ;
Dana B. Harbison ;
Marina E. Jean ;
Karen R. Cleary ;
Alan P. Dackiw ;
Robert A. Wolff ;
James L. Abbruzzese ;
Nora A. Janjan ;
Christopher H. Crane ;
J. Nicolas Vauthey ;
Jeffrey E. Lee ;
Peter W. T. Pisters ;
Douglas B. Evans .
Annals of Surgical Oncology, 2001, 8 (2) :123-132
[6]   Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].
Callery, Mark P. ;
Chang, Kenneth J. ;
Fishman, Elliot K. ;
Talamonti, Mark S. ;
Traverso, L. William ;
Linehan, David C. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733
[7]  
Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea
[8]   Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005) [J].
Corsini, Michele M. ;
Miller, Robert C. ;
Haddock, Michael G. ;
Donohue, John H. ;
Farnell, Michael B. ;
Nagorney, David M. ;
Jatoi, Aminah ;
McWilliams, Robert R. ;
Kim, George P. ;
Bhatia, Sumita ;
Iott, Matthew J. ;
Gunderson, Leonard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3511-3516
[9]  
Cox DR., 1984, Analysis of Survival Data, V1st
[10]   The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer [J].
Crane, CH ;
Varadhachary, G ;
Wolff, RA ;
Pisters, PWT ;
Evans, DB .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2006, 20 (02) :365-382